Use of proton pump inhibitors is associated with anemia in cardiovascular outpatients

Circulation Journal

Volumn 79, Issue 1, 2014, Pages 193-200

  Shikata, Toshiyuki ^a,b   Sasaki, Naoko ^c   Ueda, Masahiro ^a   Kimura, Takeshi ^a   Itohara, Kanako ^d   Sugahara, Masataka ^d   Fukui, Miho ^d   Manabe, Eri ^d   Masuyama, Tohru ^c,d   Tsujino, Takeshi ^b  

^a HYOGO COLLEGE OF MEDICINE HOSPITAL   (Japan)

^b Graduate School of Pharmacy   (Japan)

^c School of Pharmacy   (Japan)

^d HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Anemia. Cardiovascular disease. Hemoglobin. Proton pump inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTON PUMP INHIBITOR; URIC ACID; WARFARIN; CREATININE; IRON;

AGED; ANEMIA; ARTICLE; BLOOD CELL COUNT; BODY MASS; CARDIOVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; PEPTIC ULCER; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; REFLUX ESOPHAGITIS; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; BLOOD; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DEFICIENCY; HYPERLIPIDEMIAS; HYPERURICEMIA; KIDNEY DISEASES; OUTPATIENT; PEPTIC ULCER HEMORRHAGE; PERIPHERAL ARTERIAL DISEASE; POLYPHARMACY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; VITAMIN DEFICIENCY;

AGED; AGED, 80 AND OVER; ANEMIA; BLOOD CELL COUNT; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CREATININE; DIABETES MELLITUS; ERYTHROCYTE INDICES; FEMALE; HEMOGLOBINS; HUMANS; HYPERLIPIDEMIAS; HYPERURICEMIA; IRON; KIDNEY DISEASES; MALE; OUTPATIENTS; PEPTIC ULCER HEMORRHAGE; PERIPHERAL ARTERIAL DISEASE; POLYPHARMACY; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS; VITAMIN B DEFICIENCY;

EID: 84925399644     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-0582     Document Type: Article

References (33)

1. Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med 2009. 122. 896-903.
2. Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med 1994. 120. 211-215.
3. Lanas A, Bajador E, Serrano P, Fuentes J, Carreno S, Guardia J, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000. 343. 834-839.
4. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008. 118. 1894-1909.
5. Komori M, Yasaka M, Kokuba K, Matsuoka H, Fujimoto S, Yoshida M, et al. Intracranial hemorrhage during dabigatran treatment. Circ J 2014. 78. 1335-1341.
6. Kosiuk J, Koutalas E, Doering M, Nedios S, Sommer P, Rolf S, et al. Comparison of dabigatran and uninterrupted warfarin in patients with atrial fibrillation undergoing cardiac rhythm device implantations. Circ J 2014. 78. 2402-2407.
7. Yasaka M, Lip GY. Impact of non-vitamin k antagonist oral anticoagulants on intracranial bleeding in Asian patients with non-valvular atrial fibrillation. Circ J 2014. 78. 2367-2372.
8. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, et al. Anemia and mortality in heart failure patients. A systematic review and meta-analysis. J Am Coll Cardiol 2008. 52. 818-827.
9. Kaneko H, Suzuki S, Yajima J, Oikawa Y, Sagara K, Otsuka T, et al. Clinical characteristics and long-term clinical outcomes of Japanese heart failure patients with preserved versus reduced left ventricular ejection fraction. A prospective cohort of Shinken Database 2004-2011. J Cardiol 2013. 62. 102-109.
10. Miura M, Sakata Y, Nochioka K, Takada T, Tadaki S, Ushigome R, et al. Prevalence, predictors and prognosis of patients with heart failure requiring nursing care. Circ J 2014. 78. 2276-2283.
11. Tanaka S, Sakata R, Marui A, Furukawa Y, Kita T, Kimura T. Predicting long-term mortality after first coronary revascularization. The Kyoto model. Circ J 2012. 76. 328-334.
12. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009. 53. 982-992.
13. Yamada M, Wong FL, Suzuki G. Longitudinal trends of hemoglobin levels in a Japanese population. RERF’s Adult Health Study subjects. Eur J Haematol 2003. 70. 129-135.
14. Ng FH, Wong SY, Lam KF, Chang CM, Lau YK, Chu WM, et al. aspirin, clopidogrel, and enoxaparin in acute coronary syndrome. Am J Gastroenterol 2008. 103. 865-871.
15. Yano H, Tsukahara K, Morita S, Endo T, Sugano T, Hibi K, et al. Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes. A prospective, randomized, multicenter study. Circ J 2012. 76. 2673-2680.
16. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010. 363. 1909-1917.
17. Chitose T, Hokimoto S, Oshima S, Nakao K, Fujimoto K, Miyao Y, et al. on behalf of Kumamoto Intervention Conference Study (KICS) Investigators. Clinical outcomes following coronary stenting in Japanese patients treated with and without proton pump inhibitor. Circ J 2012. 76. 71-78.
18. De Domenico I, McVey Ward D, Kaplan J. Regulation of iron acquisition and storage. Consequences for iron-linked disorders. Nat Rev Mol Cell Biol 2008. 9. 72-81.
19. Andrews NC. Iron metabolism. Iron deficiency and iron overload. Annu Rev Genomics Hum Genet 2000. 1. 75-98.
20. Munoz M, Garcia-Erce JA, Remacha AF. Disorders of iron metabolism. Part 1. Molecular basis of iron homoeostasis. J Clin Pathol 2011. 64. 281-286.
21. Zhang AS, Enns CA. Molecular mechanisms of normal iron homeostasis. Hematology Am Soc Hematol Educ Program 2009. 1. 207-214.
22. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango. Regulation of mammalian iron metabolism. Cell 2010. 142. 24-38.
23. Anderson GJ, Frazer DM, McLaren GD. Iron absorption and metabolism. Curr Opin Gastroenterol 2009. 25. 129-135.
24. Anderson GJ, Vulpe CD. Mammalian iron transport. Cell Mol Life Sci 2009. 66. 3241-3261.
25. McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol 2009. 104(Suppl 2). S5-S9.
26. Krieg L, Milstein O, Krebs P, Xia Y, Beutler B, Du X. Mutation of the gastric hydrogen-potassium ATPase alpha subunit causes irondeficiency anemia in mice. Blood 2011. 118. 6418-6425.
27. Stewart CA, Termanini B, Sutliff VE, Serrano J, Yu F, Gibril F, et al. Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther 1998. 12. 83-98.
28. Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 2007. 56. 1291-1295.
29. Matsumoto M, Tsujino T, Naito Y, Lee-Kawabata M, Ezumi A, Yamamoto K, et al. Anemia as a factor that elevates plasma brain natriuretic peptide concentration in apparently healthy subjects. Int Heart J 2008. 49. 577-586.
30. Hamaguchi S, Tsuchihashi-Makaya M, Kinugawa S, Yokota T, Takeshita A, Yokoshiki H, et al. Anemia is an independent predictor of long-term adverse outcomes in patients hospitalized with heart failure in Japan. A Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009. 73. 1901-1908.
31. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981. 1. 1293-1294.
32. Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease. Results from a randomized trial. J Natl Cancer Inst 2008. 100. 996-1002.
33. Ajmal A, Gessert CE, Johnson BP, Renier CM, Palcher JA. Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels. BMC Res Notes 2013. 6. 443.